{
    "clinical_study": {
        "@rank": "82452", 
        "arm_group": [
            {
                "arm_group_label": "SM04690, 0.03mg/2mL", 
                "arm_group_type": "Experimental", 
                "description": "Single, intra-articular injection of SM04690, 0.03mg/2mL"
            }, 
            {
                "arm_group_label": "SM04690, 0.07mg/2mL", 
                "arm_group_type": "Experimental", 
                "description": "Single, intra-articular injection of SM04690, 0.07mg/2mL"
            }, 
            {
                "arm_group_label": "SM04690, 0.23mg/2mL", 
                "arm_group_type": "Experimental", 
                "description": "Single, intra-articular injection of SM04690, 0.23mg/2mL"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single, intra-articular injection of placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find the optimal dose of SM04690 that can be safely given by\n      intra-articular injection into the target knee joint of subjects with moderate to severe\n      osteoarthritis."
        }, 
        "brief_title": "Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)", 
        "condition": "Moderate to Severe Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with primary OA in target knee by American College of Rheumatology (ACR)\n             criteria\n\n          -  Screening pain criteria sufficient as assessed by WOMAC and VAS scores\n\n          -  Ability to read and understand the informed consent\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant or lactating or child bearing potential, men must use a\n             barrier method of contraception\n\n          -  Any condition, including laboratory findings, that in the opinion of the investigator\n             constitutes a risk or contraindication for participation in the study or that could\n             interfere with the study objectives, conduct or evaluation\n\n          -  Body mass index >40\n\n          -  Major knee surgery in the target knee within 12 months prior to study or planned\n             surgery during the study period\n\n          -  History of malignancy within the last 5 years\n\n          -  Participation in a clinical research trial within 12 weeks prior\n\n          -  Treatment of the target knee with intra-articular steroids within 2 months or\n             hyaluronic acid derivatives within 6 months\n\n          -  Effusion of the target knee requiring aspiration within 3 months\n\n          -  Use of electrotherapy or acupuncture for OA within 4 weeks\n\n          -  Significant and clinically evident misalignment of the target knee\n\n          -  Any known active infections\n\n          -  Any chronic condition that has not been well controlled for a minimum of 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095548", 
            "org_study_id": "SM04690-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "SM04690, 0.03mg/2mL", 
                "intervention_name": "SM04690, 0.03mg/2mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SM04690, 0.07mg/2mL", 
                "intervention_name": "SM04690, 0.07mg/2mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SM04690, 0.23mg/2mL", 
                "intervention_name": "SM04690, 0.23mg/2mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "nskrepnik@tucsonortho.com", 
                    "last_name": "Nebojsa Skrepnik, MD, PhD", 
                    "phone": "520-784-6140"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "llevy@triwestresearch.com", 
                    "last_name": "Louis Levy", 
                    "phone": "619-334-4764"
                }, 
                "facility": {
                    "address": {
                        "city": "El Cajon", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jpadaong@diabloclinical.com", 
                    "last_name": "Jessica Padaong", 
                    "phone": "925-930-7267"
                }, 
                "facility": {
                    "address": {
                        "city": "Walnut Creek", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Drarmas@wpharma.com", 
                    "last_name": "Eddie Armas", 
                    "phone": "305-665-4818"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ellenrosen@altoonaresearch.com", 
                    "last_name": "Ellen Rosen", 
                    "phone": "1-800-924-7790", 
                    "phone_ext": "224"
                }, 
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "smonday@mcrcdallas.com", 
                    "last_name": "Sara Monday", 
                    "phone": "214-424-0400"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety assessments for this study will include adverse events, dose limiting toxicity (DLT), physical exams, vital signs, ECGs, and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "during 24 weeks"
            }, 
            {
                "measure": "Additional safety assessment of bone loss as measured by CT of the knee", 
                "safety_issue": "Yes", 
                "time_frame": "during 24 weeks"
            }, 
            {
                "measure": "The following PK parameters will be determined from the plasma of SM04690; Cmax, Tmax, AUC0-t, AUC0-\u221e, and t1/2", 
                "safety_issue": "No", 
                "time_frame": "during 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095548"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline pain over the last 48 hours using a Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "during 24 weeks"
            }, 
            {
                "measure": "Change from baseline per Western Ontario and McMaster Osteoarthritis (WOMAC) assessment of disease scale", 
                "safety_issue": "No", 
                "time_frame": "During 24 weeks"
            }, 
            {
                "measure": "Change from baseline per physician global assessment of disease scale", 
                "safety_issue": "No", 
                "time_frame": "during 24 weeks"
            }, 
            {
                "measure": "Change from baseline in joint space width as measured by X-ray", 
                "safety_issue": "No", 
                "time_frame": "during 24 weeks"
            }, 
            {
                "measure": "Change from baseline of cartilage volume and thickness as measure by MRI", 
                "safety_issue": "No", 
                "time_frame": "during 24 weeks"
            }, 
            {
                "measure": "Change from baseline of biomarkers of cartilage synthesis and cytokines", 
                "safety_issue": "No", 
                "time_frame": "during 24 weeks"
            }
        ], 
        "source": "Samumed LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samumed LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}